Oruka Therapeutics, Inc. Common Stock (ORKA) is a publicly traded Healthcare sector company. As of May 21, 2026, ORKA trades at $60.67 with a market cap of $3.52B and a P/E ratio of 0.00. ORKA moved +5.49% today. Year to date, ORKA is +125.71%; over the trailing twelve months it is +471.28%. Its 52-week range spans $5.49 to $91.00. Analyst consensus is strong buy with an average price target of $137.25. Rallies surfaces ORKA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Oruka Reports 63.5% PASI 100 Rate and Raises $700M Cash: Oruka’s EVERLAST-A trial in plaque psoriasis reported a 63.5% PASI 100 rate at Week 16 and sustained IL-23 pathway inhibition with single 600 mg dosing maintaining therapeutic levels for a year. A $700 million upsized offering boosts its cash to $496 million, funding operations through the program’s BLA filing.
| Metric | Value |
|---|---|
| Price | $60.67 |
| Market Cap | $3.52B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $91.00 |
| 52-Week Low | $5.49 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-105.43M |
| Gross Margin | 0.00% |
13 analysts cover ORKA: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $137.25.